Atreca, Inc. (NASDAQ:BCEL) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET

Company Participants

Alex Gray - Head of Investor Relations

John Orwin - CEO

Tito Serafini - Chief Strategy Officer and Founder

Philippe Bishop - Chief Medical Officer

Stephen Gould - Chief Scientific Officer

Herb Cross - Chief Financial Officer

Conference Call Participants

Divya Rao - Cowen

Roger Song - Jefferies

John Newman - Canaccord

Tony Butler - EF Hutton

Stephen Willey - Stifel

Kemp Dolliver - Brookline Capital

Operator

Thank you for standing by. Welcome to the Atreca's Fourth Quarter and Year End 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions]

I'd now like to hand the call over to Head of Investor Relations, Alex Gray. Please, go ahead.

Alex Gray

Thank you, operator, and thank you to those joining us today. We pleased to host our year-end 2022 conference call and webcast, including updated data from our ongoing Phase 1b trial of ATRC-101.

Joining me for prepared remarks are John Orwin, CEO; Dr. Tito Serafini, Chief Strategy Officer and Atreca Founder; Dr. Philippe Bishop, Chief Medical Officer; and Dr. Stephen Gould, Chief Scientific Officer. Also on the line is Herb Cross, Chief Financial Officer who will be available during the Q&A session.

For those joining by phone, I'd note that we are presenting slides as part of today's program, which can be viewed via the webcast link included in our earnings release and posted to the Events and Presentation section of our Investor Relations website at ir.atreca.com. An archived replay of today's webcast and the accompanying slides will be available on our IR site, following the live presentation.

During today's call, we will be making forward-looking statements based on current expectations. These statements are subject to a number of significant risks and uncertainties, and our actual results may differ materially. For a description of risks and factors that could affect our future financial results and business, please refer the disclosure in the accompanying slides, our most recent forms 10-K and 10-Q and the reports that we may file on Form 8-K with the Securities and Exchange Commission. All our statements are made as of today, March 29, 2023, based on information currently available to us. We can give no assurance that these statements will prove to be correct. We undertake no duty to update these statements, except as required by law.